Key Triggers of Osteoclast-Related Diseases and Available Strategies for Targeted Therapies: A Review.
Key Triggers of Osteoclast-Related Diseases and Available Strategies for Targeted Therapies: A Review.
复制标题
破骨细胞相关疾病的关键触发因素和可用的靶向治疗策略：综述
DOI：
10.3389/fmed.2017.00234
复制
发表时间：
2017
影响因子：
3.9
通讯作者：
Dai M
中科院分区：
文献类型：
--
作者：
Bi H;Chen X;Gao S;Yu X;Xiao J;Zhang B;Liu X;Dai M
破骨细胞是体内唯一具有骨吸收功能的细胞，通过与成骨细胞协同作用维持骨代谢的平衡，而成骨细胞则负责骨的形成。破骨细胞的过度活性导致许多疾病，如骨质疏松症、假体周围骨质溶解、骨肿瘤和佩吉特病。相反，石骨症是由于破骨细胞缺乏引起的。现有的对抗过度活化破骨细胞和随后诱导的疾病的策略可以分为三种方法：促进破骨细胞凋亡，抑制破骨细胞生成和损害骨吸收。双膦酸盐是通过触发破骨细胞凋亡发挥作用的代表性分子。新药，如肿瘤坏死因子和核因子κ B受体激活剂配体（RANKL）抑制剂（例如，denosumab）已被开发用于靶向核因子kappa-B /RANKL/骨保护素系统或CSF-1/CSF-1 R轴的受体激活剂，这些受体激活剂在破骨细胞形成中起关键作用。此外，空泡（H+）-ATP酶抑制剂、组织蛋白酶K抑制剂和胰高血糖素样肽2损害骨吸收过程的不同阶段。最近，在这一领域取得了重大成就。本文综述了近年来破骨细胞相关疾病的研究进展以及破骨细胞形成靶向抑制剂的研究进展。
Osteoclasts, the only cells with bone resorption functions in vivo, maintain the balance of bone metabolism by cooperating with osteoblasts, which are responsible for bone formation. Excessive activity of osteoclasts causes many diseases such as osteoporosis, periprosthetic osteolysis, bone tumors, and Paget’s disease. In contrast, osteopetrosis results from osteoclast deficiency. Available strategies for combating over-activated osteoclasts and the subsequently induced diseases can be categorized into three approaches: facilitating osteoclast apoptosis, inhibiting osteoclastogenesis, and impairing bone resorption. Bisphosphonates are representative molecules that function by triggering osteoclast apoptosis. New drugs, such as tumor necrosis factor and receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors (e.g., denosumab) have been developed for targeting the receptor activator of nuclear factor kappa-B /RANKL/osteoprotegerin system or CSF-1/CSF-1R axis, which play critical roles in osteoclast formation. Furthermore, vacuolar (H+)-ATPase inhibitors, cathepsin K inhibitors, and glucagon-like peptide 2 impair different stages of the bone resorption process. Recently, significant achievements have been made in this field. The aim of this review is to provide an updated summary of the current progress in research involving osteoclast-related diseases and of the development of targeted inhibitors of osteoclast formation.
登录
查看更多内容
影响因子：
3.7
作者：
Chen ZF;Matsumura K;Wang H;Arellano SM;Yan X;Alam I;Archer JA;Bajic VB;Qian PY
通讯作者：
Qian PY
影响因子：
4.9
作者：
Garcia S;Hartkamp LM;Malvar-Fernandez B;van Es IE;Lin H;Wong J;Long L;Zanghi JA;Rankin AL;Masteller EL;Wong BR;Radstake TR;Tak PP;Reedquist KA
通讯作者：
Reedquist KA
影响因子：
6.2
作者：
Chen, Gaoping;Sircar, Kanishka;Rabbani, Shafaat A.
通讯作者：
Rabbani, Shafaat A.
影响因子：
15.9
作者：
Cenci, S;Weitzmann, MN;Pacifici, R
通讯作者：
Pacifici, R
影响因子：
44.5
作者：
Bone, Henry G.;Wagman, Rachel B.;Papapoulos, Socrates
通讯作者：
Papapoulos, Socrates